Clinical Trial Update: Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating abrocitinib for atopic dermatitis and alopecia areata in individuals with Down syndrome and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata
• Atopic Dermatitis

Drugs mentioned

• Abrocitinib (abrocitinib)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Atopic Dermatitis, Alopecia Areata | Phase 2 | Status: RECRUITING